EcoDrugPlus

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSNGAG00000013547
Gene Symbol: FLT4
3 Cross references
195 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSNGAG00000020967
Gene Symbol: FSHR
3 Cross references
199 Possible Orthologues:

Free Fatty Acid Receptor 1

Ensembl ID : ENSNGAG00000018853
Gene Symbol: FFAR1
3 Cross references
138 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSNGAG00000001262
Gene Symbol: FFAR2
3 Cross references
331 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSNGAG00000023884
Gene Symbol: FRK
3 Cross references
216 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSNGAG00000023683
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Galectin 1

Ensembl ID : ENSNGAG00000017067
Gene Symbol: LGALS1
2 Cross references
379 Possible Orthologues:

Galectin 3

Ensembl ID : ENSNGAG00000020150
Gene Symbol: LGALS3
3 Cross references
218 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Alpha 2

Ensembl ID : ENSNGAG00000018600
Gene Symbol: GABRA2
1 Cross references
253 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Epsilon

Ensembl ID : ENSNGAG00000015238
Gene Symbol: GABRE
1 Cross references
111 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSNGAG00000019531
Gene Symbol: GABRA1
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSNGAG00000004762
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).